MX2022008930A - Composiciones farmaceuticas y sus usos. - Google Patents

Composiciones farmaceuticas y sus usos.

Info

Publication number
MX2022008930A
MX2022008930A MX2022008930A MX2022008930A MX2022008930A MX 2022008930 A MX2022008930 A MX 2022008930A MX 2022008930 A MX2022008930 A MX 2022008930A MX 2022008930 A MX2022008930 A MX 2022008930A MX 2022008930 A MX2022008930 A MX 2022008930A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
relates
compounds
compositions
solvates
Prior art date
Application number
MX2022008930A
Other languages
English (en)
Inventor
Cameron Robert Stevenson
Charles Rodney Greenaway Evans
Michael Ashwood
Nicola Robas
Emily Anne Gaynor Prothero
Original Assignee
Benevolentai Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benevolentai Bio Ltd filed Critical Benevolentai Bio Ltd
Publication of MX2022008930A publication Critical patent/MX2022008930A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas, tales como composiciones tópicas, que comprenden ciertos compuestos de imidazo[1,2-b]piridazina y las sales y/o solvatos farmacéuticamente aceptables de dichos compuestos. La invención también se refiere a los procesos para la preparación de las composiciones farmacéuticas y los usos de tales composiciones en el tratamiento de enfermedades o afecciones asociadas con la actividad de la quinasa relacionada con la tropomiosina (Trk). Más específicamente, la invención se refiere a composiciones farmacéuticas tópicas que comprenden compuestos de la Fórmula (I) o sales y/o solvatos farmacéuticamente aceptables de los mismos, que son útiles para inhibir la Trk.
MX2022008930A 2020-01-22 2021-01-22 Composiciones farmaceuticas y sus usos. MX2022008930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964532P 2020-01-22 2020-01-22
PCT/GB2021/050151 WO2021148807A1 (en) 2020-01-22 2021-01-22 Pharmaceutical compositions and their uses

Publications (1)

Publication Number Publication Date
MX2022008930A true MX2022008930A (es) 2022-10-18

Family

ID=74285511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008930A MX2022008930A (es) 2020-01-22 2021-01-22 Composiciones farmaceuticas y sus usos.

Country Status (11)

Country Link
US (1) US20230112039A1 (es)
EP (1) EP4093376A1 (es)
JP (1) JP2023511172A (es)
KR (1) KR20220131267A (es)
CN (1) CN115315254A (es)
AU (1) AU2021210187A1 (es)
BR (1) BR112022013156A2 (es)
CA (1) CA3163585A1 (es)
IL (1) IL294688A (es)
MX (1) MX2022008930A (es)
WO (1) WO2021148807A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
ME02583B (me) 2011-05-13 2017-06-20 Array Biopharma Inc Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze
EP2791139B1 (en) 2011-12-12 2017-11-08 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
WO2013161919A1 (ja) 2012-04-26 2013-10-31 小野薬品工業株式会社 Ｔｒｋ阻害化合物
JP6609631B2 (ja) 2014-12-15 2019-11-20 シーエムジー ファーマシューティカル カンパニー，リミテッド 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
GB201811825D0 (en) * 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
GB201813791D0 (en) * 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds

Also Published As

Publication number Publication date
EP4093376A1 (en) 2022-11-30
WO2021148807A1 (en) 2021-07-29
AU2021210187A1 (en) 2022-07-21
CN115315254A (zh) 2022-11-08
CA3163585A1 (en) 2021-07-29
IL294688A (en) 2022-09-01
JP2023511172A (ja) 2023-03-16
BR112022013156A2 (pt) 2022-10-18
US20230112039A1 (en) 2023-04-13
KR20220131267A (ko) 2022-09-27

Similar Documents

Publication Publication Date Title
MX2021002051A (es) Imidazo[1,2-b]piridaziinas como inhibidores de trk.
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
JOP20220101A1 (ar) مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS)
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
MXPA04000905A (es) Derivados de amino-ftalazinona activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CR20230310A (es) Inhibidores de prmt5
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
JOP20220334A1 (ar) مركبات بيوتيل حلقي دايهيدروكينولين سلفوناميد
MX2021009868A (es) Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo.
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
CR20230286A (es) Inhibidores de prmt5 novedosos
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
JOP20220034A1 (ar) مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
MX2023010083A (es) Derivados heterociclicos como inhibidores de cinasas jano.
MX2021000683A (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.
MX2023009285A (es) Compuestos novedosos.